P847: MRD BY MASS SPECTROMETRY IN PERIPHERAL BLOOD AND NEXT GENERATION SEQUENCING IN BONE MARROW IN A PHASE 2 STUDY OF DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR MULTIPLE MYELOMA

• B. Derman,
• J. Rosenblatt,
• D. Avigan,
• A. Major,
• M. Rampurwala,
• D. Barnidge,
• A. Stefka,
• K. Jiang,
• A. Jakubowiak

Affiliations

B. Derman

1 Section of Hematology/Oncology, University of Chicago, Chicago

J. Rosenblatt

2 Beth Israel Deaconess Medical Center, Boston

D. Avigan

2 Beth Israel Deaconess Medical Center, Boston

A. Major

1 Section of Hematology/Oncology, University of Chicago, Chicago

M. Rampurwala

1 Section of Hematology/Oncology, University of Chicago, Chicago

D. Barnidge

3 The Binding Site Group, Rochester, MN, United States of America

A. Stefka

1 Section of Hematology/Oncology, University of Chicago, Chicago

K. Jiang

1 Section of Hematology/Oncology, University of Chicago, Chicago

A. Jakubowiak

1 Section of Hematology/Oncology, University of Chicago, Chicago